about
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology groupPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasMaternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology GroupTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaSafe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaIntegration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray studyText Mining and Data Modeling of Karyotypes to aid in Drug Repurposing Efforts.Precancerous stem cells have the potential for both benign and malignant differentiationOral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialPrevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.Infant leukemia and parental infertility or its treatment: a Children's Oncology Group report.MicroRNA profiles of drug-resistant myeloma cell lines.Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.Cytogenetics in acute leukemia.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) StudyPharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupAnalysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology GroupEnhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
P50
Q24336378-4FC60D77-10AD-4F2F-B955-5743BE8C6817Q24602856-5829E134-4855-43F7-A32A-4B66CB1C8811Q24681296-21B5794F-972F-4180-BCC3-1DE87DB42AE4Q27304652-4EC0D61C-915F-4F30-80A6-E206F7AE044DQ27824806-A7AB74C2-F21B-4A7E-9224-27E83C912328Q28239789-0B9D9935-E819-479B-BD93-BBE86DF91A45Q28261949-39C8836F-7550-4FE4-A187-BF9AFD7246CEQ28594733-7CB4C9F9-93CD-4D0A-B540-E380E6A3E099Q28834542-655B3055-202F-4D1F-9F9B-5DBBE90C0257Q29620690-F1B25264-3A0D-47CF-B581-6C63C54AFFD3Q30300395-5AACC4FB-4A44-4680-B98E-E02A743DC8C6Q30538418-73F82A7A-DF37-49FD-A85D-A672E7FF5C08Q30842603-6E6B1341-9556-43E6-98F2-32B4DC3FCAC2Q30986543-70D15EEC-DBF2-4B71-831F-56FDC77F588AQ33278288-4458B98F-75E5-400A-89D9-52B7717B9AA2Q33388076-5C0D7B2E-F5A2-4D6C-8AEC-94BD9F75B3D2Q33396918-B6162BA7-FB45-424E-B752-595C725EA3F6Q33412064-F89AAF6B-178C-46B7-B226-D22E04A6C73DQ33754603-47FFE084-D334-4256-9883-F1AD1432E5D9Q33841988-37E30F03-ADAB-4EF0-A9E2-2C001CCB495DQ33862981-8C413971-02E2-434B-9DA7-DD965FFE271BQ33898361-1A9DC1C8-4FA1-4A4D-9BF2-5D3FF637AF4FQ33987045-48695257-C179-4BD7-A989-FC798E3A77C7Q34020070-E620922D-E737-4450-9404-B24B7C40D8BBQ34052581-91FB22C9-D51E-43D1-A920-9591B05150DAQ34080807-52C275E9-F2F1-4CDE-821D-21CBE9BBC84FQ34184717-DE715D41-5B8A-4615-A9F7-A6B5D3CA09AEQ34304230-0E3A2BFD-5149-482C-973A-EB8C0E2D29F4Q34314927-4061774B-7200-458B-9CB9-E53FB6D46BF2Q34433808-23DFCEB9-492D-4E6D-AF82-150BF2CFB407Q34479465-95F30CA8-C043-4BD8-9878-0C1DF1BB0E7CQ34551046-B7BEDA51-86A9-41C4-9625-045B220B4F46Q34611637-6970BAF7-0858-4D16-97CD-3633E6E8B8E7Q34645985-D678E846-D859-4953-9749-B90178392624Q34659942-836EC5AD-95D1-4BAD-8D73-B3F33FC46661Q34667832-215D6762-E545-45D9-A241-A74F6D50B25AQ34679190-F0D6330D-13B0-4EED-8E64-AC958FA6E931Q34777365-462E9E59-45B4-4C06-AAEE-004A48A85CE2Q34879367-E6273089-DBB2-451C-939E-370026B10C83Q34918948-B0F38FC4-8757-4C96-B74F-035AFA4BF186
P50
description
researcher
@en
wetenschapper
@nl
name
Nyla A Heerema
@en
Nyla A Heerema
@nl
type
label
Nyla A Heerema
@en
Nyla A Heerema
@nl
prefLabel
Nyla A Heerema
@en
Nyla A Heerema
@nl
P31
P496
0000-0003-4910-1083